News
2018
Celsee Launches Genesis System to Overcome Prior Limits of Single-cell Analysis
Ann Arbor, Mich. – October 25, 2018 – Celsee, Inc., today launched its first product, the Genesis system, designed to overcome the limitations of… | 10/25/2018
Celsee, Inc. Enters into Supply Agreement with Argonaut Manufacturing Services
(February 14, 2018) Plymouth MI – Argonaut Manufacturing Services, a contract manufacturing organization (CMO) serving the life science and molecula… | 2/22/2018
Celsee and IncellDx Sing Co-commercialization Agreement Following Successful Lung Cancer/CTC PD-L1 Feasibility Study
Minimal expression of PD-L1 in standard-of-care methods that would have resulted in a negative call showed a positive expression using the combined ap… | 1/10/2018
2017
Zomedica Pharmaceuticals Corp. Enters Into License and Supply Agreement with Celsee, Inc. for Cancer Liquid Biopsy Platform
Targeting non-invasive veterinary cancer diagnostic assay ANN ARBOR, Mich., Dec. 21, 2017 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE Am… | 12/21/2017
Celsee Diagnostics Awarded Additional Patents for their Innovative Microfluidic Technologies
Enrich rare circulating tumor cells from whole blood then isolate and retrieve a single cell. Celsee Diagnostics, an innovator in microfluidic rare-ce… | 9/15/2017
Celsee Diagnostics Adds another Patent to IP Portfolio Expanding Protection of the Celsee PREP400 Platform
The automated Celsee PREP400 is designed for hands-free CTC capture and characterization Celsee Diagnostics, an innovator in microfluidic rare-cell is… | 7/26/2017
Celsee Diagnostics Continues to Grow IP Portfolio, Adding Three More Patents to its Expanding Library
The automated Celsee PREP400 is designed for hands-free CTC capture and characterization Celsee Diagnostics, an innovator in microfluidic rare-cell is… | 5/16/2017
Celsee Diagnostics Demonstrates New Celsee™ PREP SingleCell™ Technology at AACR Annual Meeting 2017
Innovative platform streamlines rare single-cell enrichment, characterization and retrieval Celsee Diagnostics, an innovator of cutting-edge microflui… | 4/04/2017
Celsee Diagnostics Adds Industry Veteran John L. “Kip” Miller to its Board
Celsee Diagnostics, an innovator of cutting-edge rare and single cell detection products, announced the appointment of John L. “Kip” Miller to its… | 3/15/2017
Celsee Diagnostics, IncellDx Announce Immuno-Oncology Research Agreement
Collaborative studies will focus on the use of circulating tumor cells (CTCs) as a biospecimen for PD-L1 quantification and as a tool for tailoring th… | 2/14/2017
Celsee Diagnostics Announces ISO 13485:2003 Registration
International standard registration will facilitate access to new markets Celsee Diagnostics, an innovator of cutting-edge rare cell isolation and cha… | 2/08/2017
Zomedica Announces Research Agreement with Celsee Diagnostics for Cancer Liquid Biopsy
Zomedica Pharmaceuticals Corp, (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a resea… | 1/11/2017
2016
Celsee Diagnostics Receives Patent Issuance in China for Its Fundamental Microfluidic Cell Capture Technology
Microfluidic system allows for rare single-cell enrichment, analysis and retrieval. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy pro… | 12/22/2016
Celsee Diagnostics Expands IP; Adding Another Patent for Single-Cell Capture and Retrieval Systems
Microfluidic system allows for rare single-cell enrichment, analysis and retrieval Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy prod… | 12/15/2016
Celsee Diagnostics Named PM360 Trailblazer Award Winner for Medical Device Company of the Year
Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that PM360, a leading trade magazine for marketing decision m… | 9/27/2016
Celsee Diagnostics Adds Another Patent to IP Portfolio
“System for Imaging Captured Cells” was assigned U.S. Patent No. 9404864 Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products a… | 8/03/2016
Celsee Diagnostics Adds Another Patent to IP Portfolio
Collaborative studies will determine the feasibility of using circulating tumor cells (CTCs) as a biospecimen for mutation analysis. Celsee Diagnostic… | 7/26/2016
Celsee Diagnostics selected as a 2016 Red Herring Top 100 North America winner
Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been selected as a 2016 Red Herring Top … | 6/14/2016
Biotheranostics to present feasibility data of gene expression profiling in blood
Biotheranostics, a leader in molecular diagnostics for cancer, announced results from a study developing a functional workflow for gene expression pro… | 4/22/2016
Celsee Diagnostics honored as one of the 2016 “Michigan 50 Companies to Watch”
Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been recognized as one of the 2016 “Mi… | 3/15/2016
With a new identity, liquid biopsy firm Celsee looks to move CTC isolation tech to clinic
NEW YORK (GenomeWeb) – Having recently changed its name and added new executives to its team, Plymouth, Michigan-based liquid biopsy firm Celsee Dia… | 2/16/2016
Celsee Diagnostics and collaborators publish validation study of automated CTC platform using clinical blood samples
Celsee Diagnostics, an innovator of cutting-edge products of liquid biopsy, announces the publication of “Development of an Automated and Sensitive … | 1/27/2016
Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples
Abstract. Current analysis of circulating tumor cells (CTCs) is hindered by sub-optimal sensitivity and specificity of devices or assays as well as la… | 1/05/2016
